Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Barzi on Utilizing VEGF Inhibitors Plus Immunotherapy in MSS mCRC

February 24th 2022

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

Dr. Abrams on Next Steps for Cabozantinib/Atezolizumab Combo in MSS/MMRp CRC

February 23rd 2022

Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.

Nivolumab Plus SOC Misses PFS End Point of CheckMate-9X8 Trial, But Provides Notable Benefit in Select mCRC Subsets

February 18th 2022

Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares additional insight from the CheckMate-9X8 trial, and alludes to next steps with further exploring the regimen in specific subsets who appear to derive benefit from this approach.

Rapid Readout: ctDNA Dynamics and Clinical Outcomes in the Adjuvant Management of Colorectal Cancer (GALAXY Study)

February 18th 2022

Insight on the observational GALAXY study, which analyzed the relationship between circulating tumor DNA and clinical outcomes in the adjuvant management of colorectal cancer.

Cabozantinib/Atezolizumab Combo Demonstrates Promising Clinical Activity in mCRC

February 18th 2022

Thomas A. Abrams, MD, discusses the ongoing phase 1b COSMIC-021 trial examining cabozantinib/atezolizumab, the efficacy and safety demonstrated with the regimen in those with colorectal cancer, and the next steps for research

Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRC

February 4th 2022

Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.

Dr. Ross Discusses Advances in Recognizing, Screening, and Treating CRC

February 3rd 2022

Howard M. Ross, MD, discusses advances in recognizing, screening, and treating patients with colorectal cancer.

Dr. Raghav on Potential Combinations With Trastuzumab Deruxtecan in HER2+ CRC

January 28th 2022

Kanwal P.S. Raghav, MBBS, MD, discusses potential combinations with fam-trastuzumab deruxtecan-nxki in HER2-positive colorectal cancer.

Dr. Kopetz the Current State of ctDNA Testing in CRC

January 27th 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the current state of circulating tumor DNA testing in colorectal cancer.

Future Directions for mCRC Management

January 27th 2022

Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.

Sequencing Therapy for Relapsed mCRC

January 27th 2022

Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.

Management of Relapsed mCRC

January 27th 2022

Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.

Dosing Strategies for Regorafenib for Patients With mCRC

January 27th 2022

Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.

Treatment Options After Progression on Chemotherapy/Anti-EGFR Therapy for mCRC

January 27th 2022

Experts in gastrointestinal cancers explore treatment approaches, such as with regorafenib, in patients with mCRC who have progressed on chemotherapy/anti-EGFR therapy.

Role of Maintenance Therapy in Advanced CRC

January 27th 2022

Chiara Cremolini, MD, PhD; Gerald Prager, MD; and Tanios S. Bekaii-Saab, MD, share their approach to maintenance therapy, including with EGFR inhibitors, for the management of advanced CRC.

Using ICI Therapy in MSI-High mCRC

January 27th 2022

Chiara Cremolini, MD, PhD, leads the discussion on the advantage of treating MSI-high metastatic colorectal cancer with immune checkpoint inhibitors.

Selecting Frontline Therapy for Newly Diagnosed mCRC

January 27th 2022

Tanios S. Bekaii-Saab, MD, presents the case of a 65-year-old woman with stage IV adenocarcinoma of the rectum, and the panel reviews frontline treatment options for a patient with newly diagnosed mCRC.

Dr. Barzi on the Importance of Developing Novel Therapies in Metastatic CRC

January 26th 2022

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

Utilization of ctDNA Assays Could Determine Benefit of Adjuvant Chemotherapy in Resectable CRC

January 24th 2022

The use of ctDNA assays may help identify patients with colorectal cancer who could benefit from adjuvant chemotherapy.

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

January 23rd 2022

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.